RANDOMIZED, DOUBLE-BLIND, 6-WEEK STUDY OF PREGABALIN IN SUBJECTS WITH RESTLESS LEG SYNDROME To characterize the dose-response relationship for pregabalin in the treatment of RLS symptoms in subjects with idiopathic RLS using the IRLS scale.

• Country None
• organs None
• Specialty None

A Phase 1 trial of pf‑03084014 in patients with advanced solid tumor malignancy and t‑cell acute lymphoblastic leukemia/lymphoblastic lymphoma Phase 1a Primary Objectives 1. To determine the maximum tolerated dose (MTD) of PF-03084014 when administered twice daily for 21 days alone in patients with advanced malignancies (encompassing adva...

• Country None
• organs None
• Specialty None

Study with investigational drug PF-06463922 and comparator crizotinib in patients with a specific type of advanced lung cancer - To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging progression-free survival (PFS) in advanced ALK-positive NSCLC patients who are treatme...

• Country None
• organs None
• Specialty None

A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING, STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS The primary objective of this study is to evaluate the efficacy of 4 QD dose levels (10, 30, 100, and 200 mg) of PF-04965842 relative to placebo in adult subjects with moderate to severe atopic dermat...

• Country None
• organs None
• Specialty None

PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUATE RESPONSE TO TNF INHIBITORS 1. To compare efficacy of CP 690,550 5 mg BID & 10 mg BID vs placebo for treatment of signs & symptoms of RA, in patients with RA on background MTX who have had an inadequate response (IR) to a TNF-i ...

• Country None
• organs None
• Specialty None

A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3 mg Pegaptanib Sodium (Macugen), Given as Often as Every 6 Weeks for 2 years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula The objective of this trial will be to confirm the safety and compare the efficacy of pegaptanib sodium when subjects are given intravitreous injections of 0.3 mg/eye versus sham injections in a 1:1 r...

• Country None
• organs None
• Specialty None

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE ESTUDO MULTICÊNTRICO DE FASE 3, ALEATORIZADO, EM DUPLA OCULTAÇÃO, CONTROLADO POR PLACEBO SOBRE A EFICÁCIA ANALGÉSICA E A SEGURANÇA DA ADMINISTRAÇÃO SUBCUTÂNEA DE TANEZUMAB EM DOENTES COM OSTEOARTRITE DA ANCA OU DO JOELHO •Demonstrate superior efficacy of tanezumab 5 mg and 2.5 mg administered subcutaneously (SC) every 8 weeks versus placebo at Week 24.

• Country None
• organs None
• Specialty None

EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN PATIENTS WITH CANDIDA DEEP TISSUE INFECTION • To assess the efficacy of anidulafungin and caspofungin with respect to the overall global response (clinical and microbiological success) at the EOT in subjects with a confirmed diagnosis of deep t...

• Country None
• organs None
• Specialty None

A study to measure pretection (antibody response) and safety against representative strains causing a high proportion of disease (Meningococcal Group B) in healthy subject aged between 12 and <19 years Primary Immunogenicity Objective • To describe the immune response, relative to baseline status, following receipt of Bexsero as measured by hSBA performed with a panel of MnB test strains assessed ...

• Country None
• organs None
• Specialty None

A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS SCEDOSPORIUM OR FUSARIUM SPECIES IN PEDIATRIC PATIENTS To evaluate the safety and tolerability of voriconazole as primary treatment of invasive aspergillosis and rare molds such as Scedosporium or Fusarium species in immunocompromised pediatric subjects f...

• Country None
• organs None
• Specialty None